New drug combo shows promise for kids with transplant complication
NCT ID NCT03774082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete or partial response by 7 months. Results are still being analyzed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib (a drug taken by mouth to reduce inflammation)
What this could lead to
If successful, this could offer a new treatment option for children with chronic graft-versus-host disease, helping control the condition and reduce symptoms.
What could go wrong
This is a small, early-phase trial with no placebo group, so results are preliminary. Ruxolitinib may not work for all children and can have side effects like infections or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
São Paulo, 04039 001, Brazil
-
Novartis Investigative Site
Toronto, Ontario, M5G 1X8, Canada
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Tamil Nadu, Chennai, 600035, India
-
Novartis Investigative Site
Pune, Maharashtra, 411004, India
-
Novartis Investigative Site
Bangalore, 560099, India
-
Novartis Investigative Site
Delhi, 110 085, India
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Nagoya, Aichi-ken, 466 8560, Japan
-
Novartis Investigative Site
Saitama, 330 8777, Japan
-
Novartis Investigative Site
Saint Petersburg, 197022, Russia
-
Novartis Investigative Site
Bratislava, 833 40, Slovakia
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Zurich, CH - 8032, Switzerland
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Adana, 1330, Turkey (Türkiye)
-
Novartis Investigative Site
Antalya, 07000, Turkey (Türkiye)
-
Novartis Investigative Site
Antalya, 07070, Turkey (Türkiye)